Comparison of efficacy and safety of escitalopram and vilazodone in major depressive disorder
Journal Title: National Journal of Physiology, Pharmacy and Pharmacology - Year 2018, Vol 8, Issue 8
Abstract
Background: Major depressive disorder (MDD) is a worldwide prevalent psychiatric ailment associated with significant morbidity and mortality. Escitalopram is an effective selective serotonin reuptake inhibitor (SSRI), and vilazodone is a newer SSRI and partial serotonin receptor agonist approved for MDD. Aims and Objectives: The aim was to evaluate and compare the efficacy and safety of escitalopram and vilazodone in patients of MDD. Materials and Methods: The present, randomized study was conducted in a tertiary care teaching institute, and 50 patients between 18 and 55 years of either sex diagnosed with MDD based on Diagnostic and Statistical Manual of Mental Disorders Fifth Edition criteria were included in the study. Patients were assigned randomly into two groups to receive orally either escitalopram (10 mg) or vilazodone (20 mg) and baseline scores of Hamilton Anxiety Scale (HAM–A) and Hamilton Depression Rating Scale (HAM-D) were recorded. These were then assessed at 6 weeks for post-drug scores and compared with baseline using Mann–Whitney and Wilcoxon signed-rank test statistical analytic method. Intergroup comparison was also done. Results: Average age of the patients taken was 39.74 ± 8.6 years with a male:female ratio of 19:31. The HAM-D score was significantly lowered by both escitalopram and vilazodone (P < 0.0001). HAM-A score was also similarly lowered by escitalopram (P < 0.0001) and vilazodone (P < 0.0001). On intergroup comparison, escitalopram was found to cause more lowering of HAM-D score and HAM-A score than vilazodone (P < 0.0001). Biochemical profile (blood sugar, serum urea, creatinine, hemoglobin, and total leukocyte counts) was not altered with either of the drugs over 6 weeks. No significant adverse drug reactions were noted with the drugs. Conclusion: Both drugs are effective in decreasing depression and anxiety scores in patients of MDD. On comparison, escitalopram was found better than vilazodone.
Authors and Affiliations
Palvi Kudyar, Brij Mohan Gupta, Vijay Khajuria, Rakesh Banal
Keywords
Related Articles
- EP ID EP491235
- DOI 10.5455/njppp.2018.8.0412120042018
- Views 49
- Downloads 0
Assessment of knowledge, attitude, and practice of pharmacovigilance among clinicians and postgraduate students in a teaching medical institution - A questionnaire study
Background: Spontaneous voluntary adverse drug reaction (ADR) reporting is the backbone for the successful functioning of the Pharmacovigilance Programme of India. Aims and Objectives: These study objectives were to asse...
Assessment of knowledge, attitude, and practice of pharmacovigilance among private practitioners in Southern India: A questionnaire-based study
Background: Pharmacovigilance has constantly gained importance in last 15 years, relating to absolute amount of adverse drug reactions (ADRs) and to the fact that several hospital admissions are due to ADRs. The success...
Effect of Ehretia microphylla on the blood cholesterol and weight of ICR mice (Mus musculus)
Background: Simvastatin has been widely used in controlling blood cholesterol levels and weight; however, side effects such as muscle pain, muscle damage, liver damage, and hyperglycemia may occur. Studies have shown tha...
The influence of carrageenan on markers of endogenous intoxication in rats
Background: The growth of the world population and the need to increase food production led to the widespread use of food additives. One of such additives is carrageenan. Potentially negative health effects of carrageena...
A comparative study of cardiovascular autonomic function tests between second trimester pregnant women and non-pregnant women
Background: Normal pregnancy has been documented to be accompanied by marked alteration in maternal circulation during the first and second trimesters. For adapting the cardiovascular hemodynamic changes during normal pr...